| Code | 06554 | ||||||||
| MA number | 09/0155/11-S | ||||||||
| Product Form: | tbl mnd 8 (obal PP) | ||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||
| Type of procedure: | Mutual recognition procedure | ||||||||
| MAH, country: | Reckitt Benckiser (Czech Republic), spol. s r.o. , Czechia | ||||||||
| Therapeutic Class: | 09 - ANTACIDA (VRÁTANE ANTIULCEROSNYCH LIEČIV) | ||||||||
| ATC: |
|
||||||||
| Shelf life: | 24 | ||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product not subject to medical prescription. |
| Legal basis: | Article 10a well-established use application |
| MA issued: | 29.03.2011 |
| Pediatric posology: | Yes |
| Pediatric warnings: | Yes |
| SPC: |
SPC_Gaviscon Duo Efekt Žuvacie tablety_05_2020.doc
|
| PIL: |
PIL_Gaviscon Duo Efekt Žuvacie tablety_05_2020.pdf
|
| Safety feature | No |
| Data update: | 18.04.2018 |
